BioLineRx Company Profile (NASDAQ:BLRX)

About BioLineRx (NASDAQ:BLRX)

BioLineRx logoBioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLRX
  • CUSIP: N/A
  • Web: www.biolinerx.com
Capitalization:
  • Market Cap: $117.13 million
  • Outstanding Shares: 95,617,000
Average Prices:
  • 50 Day Moving Avg: $1.13
  • 200 Day Moving Avg: $0.97
  • 52 Week Range: $0.80 - $1.38
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.96
  • P/E Growth: 0.20
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.60 per share
  • Price / Book: 1.90
Profitability:
  • EBITDA: ($18,910,000.00)
  • Return on Equity: -46.00%
  • Return on Assets: -41.39%
Debt:
  • Current Ratio: 9.92%
  • Quick Ratio: 9.92%
Misc:
  • Average Volume: 568,185 shs.
  • Beta: 0.76
  • Short Ratio: 0.72
 

Frequently Asked Questions for BioLineRx (NASDAQ:BLRX)

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). View BioLineRx's Earnings History.

When will BioLineRx make its next earnings announcement?

BioLineRx is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for BioLineRx.

Where is BioLineRx's stock going? Where will BioLineRx's stock price be in 2017?

5 analysts have issued 12-month target prices for BioLineRx's stock. Their predictions range from $3.00 to $4.00. On average, they anticipate BioLineRx's stock price to reach $3.20 in the next twelve months. View Analyst Ratings for BioLineRx.

What are analysts saying about BioLineRx stock?

Here are some recent quotes from research analysts about BioLineRx stock:

  • 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (10/3/2017)
  • 2. Maxim Group analysts commented, "BiolineRx announced the company has filed regulatory submissions for three BL-8040 + Tecentriq (PD-L1) P1b studies; pancreatic cancer, gastric cancer and lung cancer. The studies are expected to initiate in 2H17." (6/1/2017)

Who are some of BioLineRx's key competitors?

Who are BioLineRx's key executives?

BioLineRx's management team includes the folowing people:

  • Aharon Schwartz, Chairman of the Board
  • Philip Adam Serlin, Chief Executive Officer
  • Mali Zeevi, Chief Financial Officer
  • Merril Gersten, Chief Scientific Officer
  • Moshe Phillip M.D., Vice President of Medical Affairs and Senior Clinical Advisor
  • David Malek, Vice President - Business Development
  • Leah Klapper, General Manager, BioLine Innovations Jerusalem
  • Michael J. Anghel, Director
  • Jacob Friedman, Director
  • Raphael Hofstein, Director

Who owns BioLineRx stock?

BioLineRx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (24.99%). View Institutional Ownership Trends for BioLineRx.

How do I buy BioLineRx stock?

Shares of BioLineRx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioLineRx's stock price today?

One share of BioLineRx stock can currently be purchased for approximately $1.14.


MarketBeat Community Rating for BioLineRx (NASDAQ BLRX)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about BioLineRx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioLineRx (NASDAQ:BLRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.20 (180.70% upside)
Consensus Price Target History for BioLineRx (NASDAQ:BLRX)
Price Target History for BioLineRx (NASDAQ:BLRX)
Analysts' Ratings History for BioLineRx (NASDAQ:BLRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$3.00N/AView Rating Details
10/18/2017HC WainwrightSet Price TargetBuy$4.00N/AView Rating Details
8/9/2017Roth CapitalSet Price TargetBuy$3.00LowView Rating Details
8/8/2017Maxim GroupSet Price TargetBuy$3.00LowView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$3.00N/AView Rating Details
9/23/2016S&P Equity ResearchLower Price Target$1.24 -> $1.10N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$3.50 -> $3.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for BioLineRx (NASDAQ:BLRX)
Earnings by Quarter for BioLineRx (NASDAQ:BLRX)
Earnings History by Quarter for BioLineRx (NASDAQ BLRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/28/2017        
8/8/20176/30/2017($0.05)($0.05)$0.01 millionViewListenView Earnings Details
5/25/20173/31/2017($0.05)($0.08)$0.01 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.08)($0.13)$0.02 millionViewN/AView Earnings Details
11/22/2016Q316($0.07)($0.08)ViewN/AView Earnings Details
8/11/2016Q216($0.07)($0.07)ViewListenView Earnings Details
5/17/2016Q116($0.08)($0.10)ViewListenView Earnings Details
3/10/2016Q415($0.06)($0.07)ViewListenView Earnings Details
11/16/2015Q315($0.08)($0.03)ViewListenView Earnings Details
8/20/2015Q215($0.10)($0.09)ViewListenView Earnings Details
5/18/2015Q115($0.10)($0.08)ViewListenView Earnings Details
11/10/2014Q314($0.11)($0.02)ViewN/AView Earnings Details
8/6/2014Q214($0.09)($0.12)ViewN/AView Earnings Details
5/20/2014Q114($0.11)($0.01)ViewN/AView Earnings Details
3/17/2014($0.15)($0.20)ViewN/AView Earnings Details
11/13/2013($0.18)($0.20)ViewN/AView Earnings Details
8/6/2013Q213($0.02)ViewN/AView Earnings Details
5/7/2013($0.02)($0.20)ViewN/AView Earnings Details
11/14/2012Q312($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioLineRx (NASDAQ:BLRX)
2017 EPS Consensus Estimate: ($0.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($0.05)($0.05)($0.05)
Q4 20171($0.05)($0.05)($0.05)
Q1 20181($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioLineRx (NASDAQ:BLRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioLineRx (NASDAQ:BLRX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for BioLineRx (NASDAQ:BLRX)
Latest Headlines for BioLineRx (NASDAQ:BLRX)
Source:
DateHeadline
americanbankingnews.com logo-$0.05 Earnings Per Share Expected for BioLineRx Ltd. (BLRX) This Quarter
www.americanbankingnews.com - October 20 at 8:30 PM
streetinsider.com logoBioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under ... - StreetInsider.com
www.streetinsider.com - October 18 at 10:54 PM
americanbankingnews.com logoHead to Head Survey: BioLineRx (BLRX) and Its Competitors
www.americanbankingnews.com - October 18 at 10:22 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - October 18 at 8:22 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) PT Set at $3.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 18 at 7:08 PM
finance.yahoo.com logoBioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
finance.yahoo.com - October 18 at 5:53 PM
americanbankingnews.com logo-$0.05 EPS Expected for BioLineRx Ltd. (BLRX) This Quarter
www.americanbankingnews.com - October 2 at 12:20 AM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 30 at 8:34 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - September 28 at 8:00 AM
americanbankingnews.com logoContrasting BioLineRx (BLRX) & Its Rivals
www.americanbankingnews.com - September 26 at 8:22 PM
streetinsider.com logoBioLineRx (BLRX) Reports Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration - StreetInsider.com
www.streetinsider.com - September 26 at 8:11 AM
finance.yahoo.com logoBioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
finance.yahoo.com - September 26 at 8:11 AM
americanbankingnews.com logoSpectrum Pharmaceuticals (SPPI) versus BioLineRx (BLRX) Critical Analysis
www.americanbankingnews.com - September 23 at 4:20 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Given Buy Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 17 at 10:22 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Short Interest Update
www.americanbankingnews.com - September 16 at 1:44 AM
americanbankingnews.com logoBrokers Set Expectations for BioLineRx Ltd.'s FY2021 Earnings (BLRX)
www.americanbankingnews.com - September 13 at 4:46 PM
americanbankingnews.com logo Analysts Expect BioLineRx Ltd. (BLRX) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - September 13 at 6:18 AM
finance.yahoo.com logoBioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
finance.yahoo.com - September 7 at 4:49 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 11:00 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Short Interest Up 49.6% in August
www.americanbankingnews.com - August 28 at 1:48 AM
businesswire.com logoMOLOGEN AG and Chinese iPharma Ltd. signed binding term sheet for a collaboration regarding the development, manufacture and commercialization of lefitolimod in China and a ...
www.businesswire.com - August 25 at 6:20 PM
nasdaq.com logoBioLineRx Moves a Regulatory Submission for BL-8040 Trial - Nasdaq
www.nasdaq.com - August 22 at 10:16 PM
zacks.com logoBioLineRx Moves a Regulatory Submission for BL-8040 Trial
www.zacks.com - August 22 at 5:15 PM
streetinsider.com logoBioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD - StreetInsider.com
www.streetinsider.com - August 21 at 9:36 PM
streetinsider.com logoBioLineRx (BLRX) Reports Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD
www.streetinsider.com - August 21 at 4:34 PM
finance.yahoo.com logoBioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
finance.yahoo.com - August 21 at 4:34 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 11 at 11:32 PM
americanbankingnews.com logoOppenheimer Holdings Comments on BioLineRx Ltd.'s Q3 2017 Earnings (NASDAQ:BLRX)
www.americanbankingnews.com - August 11 at 9:48 AM
finance.yahoo.com logoBioLineRx Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 2:28 AM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Given a $3.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - August 8 at 6:26 PM
seekingalpha.com logoBioLineRx's (BLRX) CEO Phil Serlin on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 4:22 PM
americanbankingnews.com logoBioLineRx Ltd. (NASDAQ:BLRX) Announces Earnings Results
www.americanbankingnews.com - August 8 at 12:28 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Receives New Coverage from Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 6 at 9:06 PM
americanbankingnews.com logoBioLineRx Ltd. (BLRX) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - August 3 at 6:06 PM
americanbankingnews.com logoBioLineRx Ltd. (NASDAQ:BLRX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 10:40 AM
finance.yahoo.com logoBioLineRx to Report Second Quarter 2017 Results on August 8, 2017
finance.yahoo.com - August 2 at 5:22 PM
finance.yahoo.com logo3 Biotech Stocks to Watch in August
finance.yahoo.com - August 1 at 5:26 PM
finance.yahoo.com logo4 Biotech Stocks to Watch This Quarter
finance.yahoo.com - August 1 at 5:26 PM
seekingalpha.com logoBioLineRx investor ups stake to almost 25%; shares ahead 2% - Seeking Alpha
seekingalpha.com - July 26 at 5:10 PM
finance.yahoo.com logoBioLineRx Announces Additional Investment From BVF Partners L.P.
finance.yahoo.com - July 26 at 5:10 PM
seekingalpha.com logoInvestors Waiting In BioLineRx - Seeking Alpha
seekingalpha.com - July 18 at 6:06 PM
americanbankingnews.com logoBioLineRx Ltd. (NASDAQ:BLRX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 17 at 11:14 PM
seekingalpha.com logoBioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy - Seeking Alpha
seekingalpha.com - July 13 at 5:35 PM
streetinsider.com logoBioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration - StreetInsider.com
www.streetinsider.com - July 11 at 4:54 PM
finance.yahoo.com logoBioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
finance.yahoo.com - July 10 at 4:34 PM
streetinsider.com logoBioLineRx (BLRX) Announces Submission of Three Phase 1b Trials ... - StreetInsider.com
www.streetinsider.com - June 1 at 4:25 PM
prnewswire.com logoBioLineRx Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 25 at 5:01 PM
streetinsider.com logoBioLineRx (BLRX) Files BL-8040 Phase 1b Trial Regulatory Submission in Combo with atezolizumab in AML - StreetInsider.com
www.streetinsider.com - May 24 at 8:53 PM
streetinsider.com logoBioLineRx (BLRX) Initiate Phase 3 Study with BL-8040 Following Successful Meeting with FDA - StreetInsider.com
www.streetinsider.com - May 3 at 10:48 AM
seekingalpha.com logoBiolineRx: COMBAT Engagement - Seeking Alpha
seekingalpha.com - April 20 at 4:03 PM

Social

Chart

BioLineRx (BLRX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.